Allarity Therapeutics, Inc. 10-Q

Item 5. Other Information. None of our directors or officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement (as defined in Item 408 (c) of Regulation S-K) during the first quarter of 2026 . 19 Table of Contents Item 6. Exhibits. See the Exhibit Index to this Quarterly Report immediately below and before the signature page hereto, which Exhibit Index is incorporated by reference as if fully set forth herein. Incorporated by Reference Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Filed Herewith 3.1 Certificate of Incorporation S-4 333-258968 3.1 August 20, 2021 3.2 Certificate of Amendment to the Certificate of Incorporation of Allarity Therapeutics, Inc. S-4/A 333-259484 3.3 September 29, 2021 3.3 Second Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. 8-K 001-41160 3.1 March 20, 2023 3.4 Third Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. 8-K 001-41160 3.1 March 24, 2023 3.5 Fourth Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. 8-K 001-41160 3.1 June 28, 2023 3.6 Fifth Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. 8-K 001-41160 3.1 April 4, 2024 3.7 Specimen Common Stock Certificate of Allarity Therapeutics, Inc. S-4/A 333-259484 4.1 September 29, 2021 3.8 Amended and Restated Bylaws of Allarity Therapeutics, Inc. S-4/A 333-259484 3.4 October 18, 2021 3.9 Amendment No. 1 to Amended and Restated Bylaws of Allarity Therapeutics, Inc. 8-K 001-41160 3.1 July 11, 2022 3.10 Sixth Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. 8-K 001-41160 3.1 September 9, 2024 3.11 Seventh Certificate of Amendment to Certificate of Incorporation of Allarity Therapeutics, Inc. 8-K 001-41160 3.2 September 9, 2024 3.12 Certificate of Correction to the Seventh Certificate of Amendment to the Certificate of Incorporation of Allarity Therapeutics, Inc. 8-K/A 001-41160 3.3 September 10, 2024 4.1 Secured Promissory Note A-1, dated March 2, 2026. 8-K 001-41160 4.1 March 6, 2026 4.2 Secured Promissory Note B, dated March 2, 2026. 8-K 001-41160 4.2 March 6, 2026 10.1 Common Stock Purchase Agreement, dated as of January 28, 2026, by and between the Company and Tumim Stone Capital, LLC. 8-K 001-41160 10.1 January 29, 2026 10.2 Note Purchase Agreement, dated March 2, 2026. 8-K 001-41160 10.1 March 6, 2026 10.3 Deposit Account Control Agreement, dated March 2, 2026. 8-K 001-41160 10.2 March 6, 2026 10.4 Guaranty, dated March 2, 2026. 8-K 001-41160 10.3 March 6, 2026 10.5 Pledge Agreement, dated March 2, 2026. 8-K 001-41160 10.4 March 6, 2026 31.1 Certifications of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act X 31.2 Certifications of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act X 32* Section 1350 Certifications of Chief Executive Officer and Chief Financial Officer — 101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) X 101.SCH Inline XBRL Taxonomy Extension Schema Document X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X 101PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X 104* The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL (included in Exhibit 101) — * Furnished herewith. 20 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALLARITY THERAPEUTICS, INC., Date: May 15, 2026 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer (Principal Executive Officer) Date: May 15, 2026 By: /s/ Jeffrey S. Ervin Jeffrey S. Ervin Chief Financial Officer (Principal Financial Officer) 21